Market News AIOpen the app

PDS Biotechnology lost $7.6 million last quarter, but it's an improvement from last year.

ResultsRead the original at globenewswire.com
Good for PDSB

PDS Biotechnology narrowed its loss and cut operating costs, which supports improvement. Some savings came from clinical-trial spending, and the report gave no new trial results despite $15.2 million in cash.

PDSB · PDS Biotechnology Corporation

AI read · Good for PDSB

The AI's read

Lower spending can help conserve cash, but some savings came from clinical-trial costs. PDS Biotechnology reported $15.2 million in cash, and its PDS0301 trials remain ongoing with no new results reported.

Get alerts for PDSB

Follow PDS Biotechnology Corporation (PDSB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PDSB
Free on the App Store and Google Play, or on the web.